Cholinergic inhibitors, particularly cholinesterase inhibitors (ChEIs), like donepezil, rivastigmine, and galantamine, are Food and Drug Administration (FDA) approved and effective for mild to moderate AD, working by inhibiting the breakdown of acetylcholine [5,6], which is crucial for cognitive function. Here, BCHE is linked to Alzheimer disease.